A16AX06 • miglustat • Alimentary tract and metabolism | Other alimentary tract and metabolism products | Various alimentary tract and metabolism products
Miglustat is a glucosylceramide synthase inhibitor used for the treatment of type 1 Gaucher disease and Niemann-Pick type C disease. It works by reducing the production of glycosphingolipids, which accumulate in cells due to these conditions.
The medication is taken orally, usually three times daily, with the dose adjusted based on the patient's weight and response to treatment. Common side effects include diarrhea, flatulence, abdominal pain, and weight loss.
Miglustat is contraindicated in patients with severe renal impairment or hypersensitivity to the active substance. Its use also requires careful monitoring of gastrointestinal function and body weight.
This medication is an important option for managing lysosomal storage disorders, helping to alleviate symptoms and slow disease progression.
Substance: miglustat
Date of last drug list: 01-06-2025
Commercial code: W65802002
Concentration: 100mg
Pharmaceutical form: capsules
Quantity: 84
Product type: generic
Price: 11598.08 RON
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: G.L. PHARMA GMBH - AUSTRIA
Holder: ACCORD HEALTHCARE POLSKA SP. Z O.O. - POLONIA
Number: 10678/2018/02
Shelf life: 4 years
GX (C1) - GENERIC (used in compensation list, C1, for another diagnosis)
Price
Copayment
Patient
11598.08 RON
11598.08 RON
0.00 RON